Influence of primary tumor resection on survival in asymptomatic patients with incurable stage IV colorectal cancer

Akira Watanabe(Shizuoka Cancer Center), Hirofumi Yasui(Shizuoka Cancer Center), Akiko Todaka(Shizuoka Cancer Center), Kentaro Yamazaki(Shizuoka Cancer Center), Yusuke Kinugasa(The Japanese Society of Gastroenterological Surgery), Shunsuke Tsukamoto(Tokyo Medical University Hospital), Tomoya Yokota(Target (United States)), Akio Shiomi(Shizuoka Cancer Center), Nozomu Machida(Shizuoka Cancer Center), Yusuke Onozawa(Shizuoka Cancer Center), Takahiro Tsushima(Shizuoka Cancer Center), Tomohiro Yamaguchi(Japanese Foundation For Cancer Research), Akira Fukutomi(Shizuoka Cancer Center)
International Journal of Clinical Oncology
February 14, 2014
10.1007/s10147-014-0662-x
Cited by 25

Related Papers

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
|The Lancet Oncology|2015|954
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
|British Journal of Cancer|2010|749
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632